HawkEye 360 and Leonardo S.p.A. signed a Memorandum of Understanding to integrate HawkEye 360's radio-frequency sensing technology into Leonardo's space services. This collaboration aims to develop a sovereign, multi-sensor intelligence solution tailored for European customers, enhancing data sovereignty and operational capabilities. The initial phase includes exclusive RF data capacity for specific European areas, delivered via EU-based infrastructure to reduce latency. The partnership also plans future cooperation on payload technologies and interoperability to strengthen Europe's intelligence capabilities.
HawkEye 360 and Leonardo's new collaboration comes as 61 of 150 Technology-sector US stocks on Pluang rose today. For readers following Technology stocks, here is Pluang's market snapshot as of Sep 15, 2026 13:11 WIB: HubSpot Inc (HUBS) led with a 10.28% gain to USD 248.50, followed by Expensify Inc (EXFY) up 9.72% at USD 2.37, and Wix.Com Ltd (WIX) rising 9.04% to USD 83.50. Overall, 82 stocks fell in this sector on the day.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
